Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

OBJECTIVES The aim of this study was to evaluate the correlation between liver function markers (necrosis and cholestasis) and plasma lopinavir levels in a cohort of HIV-infected patients treated with lopinavir and ritonavir. PATIENTS AND METHODS The blood samples for determining steady-state C(trough) lopinavir levels and analysing liver function were drawn from fasting patients. Steady-state C(trough) lopinavir levels, liver function and immuno-virological markers were assessed on the same day. Plasma lopinavir and ritonavir levels were determined by means of high-performance liquid chromatography. RESULTS One hundred and forty-nine patients were included in the analysis [57 were HCV co-infected (34%) and 10 were HBV co-infected (6.7%)]; they had been treated with lopinavir/ritonavir for a median of 232 days (range 132-282). All patients received lopinavir/ritonavir [400/100 mg twice daily or 533/133 mg twice daily if amprenavir or a non-nucleoside reverse transcriptase inhibitor (NNRTI) was part of therapy] and concomitant therapy with NRTI(s). Median (interquartile) lopinavir trough levels were 6391 ng/mL (4121-8726), 5662 (3585-8893) and 6819 ng/mL (5324-8726) in the patients with HIV alone and those with HIV/HCV (or HBV) co-infection, respectively (P = not significant). Univariate analysis showed a significant association between the cholestasis markers and C(trough) lopinavir level. Multivariate analysis selected only gamma glutamyltranspeptidase (GGT) (OR = 1.010, 95% CI: 1.002-1.021) as being independently associated with plasma lopinavir levels of >6425 ng/mL; alkaline phosphatase (OR = 1.004, 95% CI: 1.000-1.010; P = 0.08) and total bilirubin (OR = 3.118, 95% CI: 0.980-11.715; P = 0.07) were not associated. CONCLUSIONS Elevated lopinavir concentrations are associated with raised GGT.

[1]  F. D. De Rosa,et al.  Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. , 2005, The Journal of antimicrobial chemotherapy.

[2]  Richard D Moore,et al.  Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir , 2004, AIDS.

[3]  D. Dieterich,et al.  Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.

[4]  P. Duca,et al.  Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevation , 2004, HIV medicine.

[5]  V. Soriano,et al.  Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. , 2004, AIDS research and human retroviruses.

[6]  K. Teruya.  [Hepatitis C in the HIV-infected person]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[7]  T. Allègre,et al.  Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. , 2004, British journal of clinical pharmacology.

[8]  M. Bonacini.  Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  C. Quantin,et al.  Acute Liver Enzyme Elevations in HIV-1-Infected Patients , 2003, HIV clinical trials.

[10]  G. Beall,et al.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.

[11]  J. Rockstroh,et al.  Antiretroviral drug toxicity -- a challenge for the hepatologist? , 2002, Journal of hepatology.

[12]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[13]  B. Sadler,et al.  Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function , 2000, Antimicrobial Agents and Chemotherapy.

[14]  David Back,et al.  Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.

[15]  J. Gerber,et al.  Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.